Quintiles Increases Contract Win Rate But Suffers From Halt Of Antiplatelets
Executive Summary
Quintiles has won about 550 contract bid proposals for drug development work in the U.S. during the first seven months of 1999, according to figures on its success rate provided to analysts during a Sept. 17 conference call.
You may also be interested in...
Novartis Reduces Outsourcing Through Parexel; CRO To Lay Off 400-500
Novartis' cancellation of several outsourcing contracts with Parexel could result in a reduction of the contract research organization's workforce by 400-500 positions, Parexel said.
Novartis Reduces Outsourcing Through Parexel; CRO To Lay Off 400-500
Novartis' cancellation of several outsourcing contracts with Parexel could result in a reduction of the contract research organization's workforce by 400-500 positions, Parexel said.
Parexel's Reorganized Research Segment Includes Small-Company Specialty
Parexel will create a unit dedicated to small biotech and pharmaceutical businesses as part of a reorganization of the company's contract research segment.